83-5968-26　Natalizumab Biosimilar, Integrin alpha 4 5mg　592035

特徴

• Natalizumab Biosimilar uses the same protein sequences as the therapeutic antibody natalizumab.
• Natalizumab is a monoclonal anti-integrin antibody which binds to the alpha 4 subunit of integrins to prevent migration of immune cells, and is used to treat Crohn's disease or multiple sclerosis.
• Humanized IgG4,k monoclonal antibody produced in murine myeloma cells.
• Natalizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to a4-integrin.
• Binds to the α4-subunit of α4b 1 and α4b 7 integrins expressed on the surface of all leukocytes except neutrophils, and inhibits the α4-mediated adhesion of leukocytes to their counter-receptor(s).
• Applications:Suitable for use in ELISA, Neutralization, Functional Assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by Natalizumab.
• Other applications not tested.
• Recommended Dilution:Optimal dilutions to be determined by the researcher.
• Storage and Stability:May be stored at 4℃ for short-term only.
• Aliquot to avoid repeated freezing and thawing.
• Store at -20℃.
• Aliquots are stable for 12 months after receipt.
• For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.